ARTV
Price
$6.56
Change
+$0.67 (+11.38%)
Updated
Oct 20 closing price
Capitalization
320.72M
21 days until earnings call
Intraday BUY SELL Signals
SLXN
Price
$0.15
Change
-$0.00 (-0.00%)
Updated
Oct 20 closing price
Capitalization
855.17K
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARTV vs SLXN

ARTV vs SLXN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARTV vs. SLXN commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTV is a Hold and SLXN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARTV with price predictions
Oct 20, 2026

ARTV in downward trend: 10-day moving average broke below 50-day moving average on September 15, 2026

The 10-day moving average for ARTV crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARTV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for ARTV entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARTV's RSI Oscillator exited the oversold zone, 9 of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for ARTV just turned positive on October 19, 2026. Looking at past instances where ARTV's MACD turned positive, the stock continued to rise in 19 of 20 cases over the following month. The odds of a continued upward trend are 90%.

Following a +12.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARTV advanced for three days, in 95 of 108 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

ARTV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.923) is normal, around the industry mean (3.009). P/E Ratio (-2.031) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (81.301) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ARTV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARTV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SLXN with price predictions
Oct 20, 2026

SLXN in -4.04% downward trend, falling for three consecutive days on October 14, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SLXN declined for three days, in 184 of 201 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLXN as a result. In 28 of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 42%.

The Aroon Indicator for SLXN entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +43.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLXN advanced for three days, in 53 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

SLXN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.436) is normal, around the industry mean (3.009). P/E Ratio (-0.008) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. SLXN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLXN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
ARTVSLXN
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
62%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
42%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend about 1 month ago
56%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (ARTV: $6.56 vs. SLXN: $0.15)
Brand notoriety: ARTV and SLXN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTV: 91% vs. SLXN: 24%
Market capitalization -- ARTV: $320.72M vs. SLXN: $855.17K
ARTV [@Biotechnology] is valued at $320.72M. SLXN’s [@Biotechnology] market capitalization is $855.17K. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.44B. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTV’s FA Score shows that 1 FA rating(s) are green while SLXN’s FA Score has 0 green FA rating(s).

  • ARTV’s FA Score: 1 green, 4 red.
  • SLXN’s FA Score: 0 green, 5 red.
According to our system of comparison, ARTV is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTV’s TA Score shows that 5 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).

  • ARTV’s TA Score: 5 bullish, 3 bearish.
  • SLXN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ARTV is a better buy in the short-term than SLXN.

Price Growth

ARTV (@Biotechnology) experienced а +4.29% price change this week, while SLXN (@Biotechnology) price change was -12.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.

Reported Earning Dates

ARTV is expected to report earnings on Nov 11, 2026.

SLXN is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARTV
Daily Signal:
Gain/Loss:
SLXN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FIGG17.551.78
+11.29%
Leverage Shares 2x Long FIG Daily ETF (FIGG)
NBIL13.090.17
+1.32%
GraniteShares 2x Long NBIS Daily ETF (NBIL)
XDSQ45.090.08
+0.18%
Innovator US Equity Accelerated ETF (XDSQ)
XLI166.800.12
+0.07%
State Street Industrial Select Sector SPDR ETF (XLI)
SCHJ24.14-0.02
-0.08%
Schwab 1-5 Year Corporate Bond ETF (SCHJ)